CB-307

N/A

Report date: 2026/05/20 20:02:01
First In Class

Base Information

Drug NameCB-307
Drug Alias NameCB-307CB307
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragmentBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody +[4] 
Mechanisms of ActionImmunomodulatorsT lymphocytes stimulantsTumor necrosis factor receptor superfamily member 9 agonists +[5] 
TargetsTumor necrosis factor receptor superfamily member 9Prostate-Specific Membrane AntigenAlbumins
Therapy Area/IndicationsProstatic Neoplasms, Castration-ResistantNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlandsUnited Kingdom +[4] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCrescendo Bioscience Inc
China Registration ClassN/A

Develop Information

Active CompaniesCrescendo Biologics Ltd
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms, Castration-ResistantNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A